CD69 on CD56+ NK cells and response to chemoimmunotherapy in metastatic melanoma.
BACKGROUND
The few chemoimmunotherapy trials that together with dacarbazine (DTIC) and interferon-alpha 2a (IFNalpha), include retinoic acid (RA), did not include detailed immunological evaluation of functional and phenotypic natural killer (NK) cell characteristics, and have shown contradictory clinical results.


METHODS
Malignant melanoma (MM) patients undergoing phase II-randomized chemoimmunotherapy trials were treated with DTIC, IFNalpha (Hoffmann-La Roche) (group A, n = 31), and with DTIC, IFNalpha and 13-cis-RA (Isotretinoin, Hoffmann-La Roche, Basel, Switzerland) (group B, n = 29). Patients and 42 healthy controls were evaluated by FACS flow analyses for CD3/CD56/CD69 positive cells, NK cytotoxicity in fresh peripheral blood lymphocytes (PBL) and for interferon regulatory factor-1 mRNA expression by reverse transcriptase polymerase chain reaction in treated PBL.


RESULTS
The addition of RA to a DTIC-IFN regime did not bring any therapeutical benefit in terms of response or survival. Immunological follow-up on days 1, 6 and 27 of each therapy cycle shows a significant increase in NK cell activity in both groups, only on day 6 of the first cycle, while CD69+CD56+ expression increased significantly on day 6 of each therapy cycle, in both groups. Evaluation of the dynamics of expression of IRF-1 of in vitro treated PBL, shows its strong and prompt up-regulation by IFNalpha and synergistic effect of IFNalpha and RA combination.


CONCLUSIONS
The dynamics of the increase in CD69 early activation antigen expression on CD56+ NK cells is systematic and serial with the increase being significantly higher on day six of the first cycle in group B patients with clinical response, compared to those without, indicating possible predictive value of CD69 expression for clinical response to chemoimmunotherapy.
Konjević
G
G
Institute for Oncology and Radiology of Serbia, Pasterova 14, Belgrade, Serbia and Montenegro. konjevicg@ncrc.ac.yu
Jović
V
V
Vuletić
A
A
Radulović
S
S
Jelić
S
S
Spuzić
I
I
D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000276:immunology / Q000378:metabolism*; D000945:Antigens, Differentiation, T-Lymphocyte / Q000276:immunology / Q000378:metabolism*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D019002:CD56 Antigen / Q000276:immunology / Q000378:metabolism*; D016022:Case-Control Studies; D003606:Dacarbazine / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D050856:Interferon Regulatory Factor-1 / Q000276:immunology; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage; D007694:Killer Cells, Natural / Q000276:immunology; D037181:Lectins, C-Type; D008297:Male; D008545:Melanoma / Q000276:immunology / Q000628:therapy*; D008875:Middle Aged; D011994:Recombinant Proteins; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods; D012878:Skin Neoplasms / Q000276:immunology / Q000628:therapy*; D014212:Tretinoin / Q000008:administration & dosage; D000099192:CD69 Antigens
D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D019002:CD56 Antigen; D003606:Dacarbazine; D050856:Interferon Regulatory Factor-1; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D037181:Lectins, C-Type; D011994:Recombinant Proteins; D014212:Tretinoin; D000099192:CD69 Antigens; C494257:IRF1 protein, human